The randomized study lasted just 3 months, but researchers saw “multiple cardiometabolic benefits” beyond weight loss.
Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.
Weekend warriors have a similarly low risk of disease and cardiometabolic health as those who spread exercise out evenly.
Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.
While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...
With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback